Trading Signals: SGEN Stock Price Prediction and Forecast (Fri. May. 30, 2003 - Wed. Dec. 13, 2023)(Seattle Genetics, Inc.)
| SGEN latest price $46.3000 (-0.15%) ($46.0600 - $47.3900) on Fri. Aug. 18, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.41% (three month average) | RSI | 26 | Latest Price | $46.3000(-0.15%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SGEN declines -2.8% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support SGEN advance at 0% a week (0% probability) IBB(35%) XLV(31%) XBI(29%) IVW(28%) IWF(28%) | Factors Impacting SGEN price | SGEN will decline at least -1.205% in a week (0% probabilities). VIXM(-12%) UUP(-7%) TLT(-4%) SHY(-2%) GDXJ(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.205% (StdDev 2.41%) | Hourly BBV | 0 () | Intraday Trend | -0.3% | | | |
|
1 - 5 Day Possible Target | $35.97(-22.31%) | Resistance Level | $49.18 | 5 Day Moving Average | $46.52(-0.47%) | 10 Day Moving Average | $47.12(-1.74%) | 20 Day Moving Average | $49.18(-5.86%) | To recent high | -31.4% | To recent low | 0.8% | Market Cap | $8.05b | | | | Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. |